Birmingham Capital Management Co. Inc. AL Acquires New Shares in Cardinal Health, Inc. $CAH

Posted by Geri Gentry on Aug 27th, 2026

Birmingham Capital Management Co. Inc. AL bought a new stake in Cardinal Health, Inc. (NYSE:CAH – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,300 shares of the company’s stock, valued at approximately $1,497,000.

Several other hedge funds also recently bought and sold shares of CAH. BlackRock Inc. acquired a new stake in shares of Cardinal Health during the 2nd quarter valued at about $6,293,115,000. State Street Corp increased its holdings in Cardinal Health by 1.8% in the fourth quarter. State Street Corp now owns 12,509,230 shares of the company’s stock worth $2,570,647,000 after buying an additional 221,497 shares during the last quarter. Geode Capital Management LLC raised its position in Cardinal Health by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 6,529,013 shares of the company’s stock valued at $1,336,750,000 after acquiring an additional 43,924 shares in the last quarter. Wellington Management Group LLP raised its position in Cardinal Health by 153.2% during the third quarter. Wellington Management Group LLP now owns 5,804,090 shares of the company’s stock valued at $911,010,000 after acquiring an additional 3,511,579 shares in the last quarter. Finally, Norges Bank acquired a new stake in Cardinal Health in the fourth quarter valued at approximately $790,344,000. 87.17% of the stock is owned by institutional investors and hedge funds.

Cardinal Health Stock Up 0.3%

Shares of Cardinal Health stock opened at $238.61 on Thursday. Cardinal Health, Inc. has a 12-month low of $145.87 and a 12-month high of $258.30. The stock has a 50 day moving average price of $232.59 and a two-hundred day moving average price of $218.25. The stock has a market capitalization of $55.50 billion, a P/E ratio of 33.00, a PEG ratio of 1.43 and a beta of 0.49.

Cardinal Health (NYSE:CAH – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The company had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. During the same quarter last year, the firm posted $2.08 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Sell-side analysts anticipate that Cardinal Health, Inc. will post 12.55 earnings per share for the current year.

Cardinal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be issued a $0.5158 dividend. This represents a $2.06 annualized dividend and a yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is 28.49%.

Analysts Set New Price Targets

Several analysts have commented on CAH shares. Royal Bank Of Canada initiated coverage on shares of Cardinal Health in a research report on Wednesday, August 19th. They issued an “outperform” rating and a $276.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of Cardinal Health from $215.00 to $260.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Robert W. Baird lifted their price objective on shares of Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Citigroup increased their target price on shares of Cardinal Health from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, TD Cowen raised their target price on Cardinal Health from $275.00 to $280.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $266.56.

View Our Latest Analysis on Cardinal Health

Insider Activity

In other Cardinal Health news, CEO Deborah Weitzman sold 7,354 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the completion of the transaction, the chief executive officer owned 77,901 shares of the company’s stock, valued at $18,341,790.45. The trade was a 8.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen M. Mason sold 35,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $236.40, for a total transaction of $8,274,000.00. Following the sale, the chief executive officer owned 18,061 shares of the company’s stock, valued at $4,269,620.40. This trade represents a 65.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 210,271 shares of company stock worth $49,626,657. Insiders own 0.12% of the company’s stock.

Cardinal Health Company Profile

(Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.